|
Match
|
Document |
Document Title |
|
|
6395879 |
Monoclonal antibodies against Campylobacter jejuni and Campylobacter coli outer membrane antigens
The present invention is directed to a method of producing monoclonal antibodies that are highly specific for (1) unique epitopes of Campylobacter jejuni (Cj) only and (2) epitopes conserved...
|
|
|
6391568 |
Method for determining platelet reactivity in a whole blood sample
The present invention provides a method for the quantification and assessment of platelet activation in whole blood samples and monitoring of antiplatelet pharmacologic agents. The method for...
|
|
|
6387698 |
MAGE-10 encoding CDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof
Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are part of the invention.
|
|
|
6383487 |
Methods of treatment using CD25 binding molecules
Novel monoclonal antibodies to the CD25 antigen are characterized by the amino acid sequence of their hypervariable regions. Initially produced in murine form, they may be converted to chimeric or...
|
|
|
6384198 |
Methods for inhibiting the production of HIV-1 retrovirus using monoclonal antibodies and Fv specific for CD2 antigen
An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric nonclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia...
|
|
|
6379953 |
Ligands that modulate differentiation of mesenchymal stem cells
Disclosed are compositions and methods for accelerating the differentiation of human MSCs into the osteogenic lineage with resultant enhanced de novo bone formation. This makes possible improved...
|
|
|
6375950 |
Methods for inducing T cell unresponsiveness to donor tissue or organ in a recipient with gp39 antagonists
Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which...
|
|
|
6369204 |
Antibodies to αvβ3 integrin
The invention relates to monoclonal antibodies to the αvβ3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption....
|
|
|
6365716 |
Antibodies to lipocalin homologs
The present invention is directed to antibodies to polypeptides for a member of the lipocalin family. The expression of the polypeptide is restricted to testis and mammary gland, particularly...
|
|
|
RE37596 |
Monoclonal antibodies against tumor-associated antigens, a process for the preparation thereof and the use thereof
The invention relates to monoclonal antibodies (MAbs) and fragments thereof which bind to defined tumor-associated antigens, principally of small cell lung carcinoma (SCLC), of melanoma, of...
|
|
|
6355244 |
Methods and compositions for the treatment of psoriasis
This invention provides methods of treating psoriasis which entail eliciting an immune response in an individual against an antigen aberrantly expressed in psoriatic tissue, such as a ganglioside,...
|
|
|
6350449 |
Antibodies to meningococcal polysaccharide conjugate vaccines
The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis . The invention also provides vaccines in which the respective modified polysaccharides are...
|
|
|
6350450 |
TIE ligand homologue antibody
The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5 and NL8, the proteins encoded by such nucleic acid molecules, as well as methods and means for...
|
|
|
6350854 |
Isolated 55 to 72 kDa protein which binds to prion proteins
The invention involves an isolated anti-prion-protein binding protein that has a molecular weight of about 55 kD to about 72 kD as determined by SDS-PAGE. Also described is a peptide derived from...
|
|
|
6346248 |
Methods of treating autoimmune diseases with a CD86-specific immunotoxin
A method for treating autoimmune diseases comprising administering to a patient in need of such treatment a therapeutically effective amount of an immunotoxin comprising an anti-human CD86...
|
|
|
6340459 |
Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
Activation of cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the cells with an agent capable of inhibiting interaction between CD40 ligand and the cells, in an...
|
|
|
6340571 |
Antibodies specific for Staphylococcus aureus, and use thereof
A monoclonal or polyclonal antibody specific for an epitope common to Staphylococcus aureus strains of various capsular serotypes, particularly methicillin-resistant strains, the antibody being...
|
|
|
6331286 |
Methods for high energy phototherapeutics
Methods of treating and imaging diseased tissue having the steps of administering a radiosensitizer agent proximate to or into the diseased tissue; and treating the diseased tissue with x-rays or...
|
|
|
6331615 |
Nucleic acid molecule encoding heavy or light chain of an antibody which specifically recognizes a protein specifically recognized by monoclonal antibody 5c8 (anti-CD40 ligand)
The present invention provides for an isolated nucleic acid molecule encoding a light chain protein of an antibody, wherein the antibody binds specifically to a protein specifically recognized by...
|
|
|
6328964 |
Method to treat multiple sclerosis with GP39-specific antibodies
Method for the treatment of multiple sclerosis and other T cell mediated autoimmune disorders is described. The method involves administering to a subject a therapeutically effective amount of an...
|
|
|
6319499 |
Methods for activating an erythropoietin receptor using antibodies
Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and...
|
|
|
6315998 |
Methods of blocking B-cell activation using anti-CD40 monoclonal antibodies
Methods for preventing or treating an antibody-mediated diease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen...
|
|
|
6316601 |
Antibodies specific for β6 integrins
Antibodies specific for β 6 integrins are provided.
|
|
|
6312693 |
Antibodies against human CD40
The Applicants have discovered humanized anti-human CD40 antibodies which block the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating...
|
|
|
6312692 |
Method of treating graft-versus-host disease with anti-GP39 antibodies and bone marrow cells
A method of treating graft-vs-host diseases by administration of bone marrow and an anti-gp39 antibody specific to human gp39 is provided.
|
|
|
6309639 |
Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [ 3 ...
|
|
|
6309637 |
Human microfibril-associated glycoprotein 4 splice variant
The invention provides a human microfibril-associated glycoprotein 4 splice variant (MAG4V) and polynucleotides which identify and encode MAG4V. The invention also provides expression vectors, host...
|
|
|
6309863 |
Methods for generating phosphorylation site-specific immunological reagents
The present invention provides methods for generating phosphorylation site-specific immunological reagents. More specifically, a phosphopeptide mimetic is incorporated into a polypeptide in place...
|
|
|
6306615 |
Detection method for monitoring β tubulin isotype specific modification
This invention relates to monoclonal antibodies that recognize modified β-tubulin isotypes, methods of using such antibodies to detect modified β-tubulin isotypes, methods of using such...
|
|
|
6306393 |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to...
|
|
|
6307026 |
Humanized antibodies directed against A33 antigen
A33 antigen binding proteins are described for use in the diagnosis or treatment of colorectal tumors and metastases arising therefrom. The binding protein may be a humanized A33 antibody,...
|
|
|
6303755 |
Therapeutic multispecific compounds comprised of anti-FCA receptor antibodies
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies and methods of use are provided.
|
|
|
6294172 |
Monoclonal antibodies with specificity for membrane-associated antigens
Monoclonal antibodies with specificity for membrane-associated antigens and methods of using them in detection of tumor-associated antigens arc described.
|
|
|
6294654 |
Modified immunoglobulin molecule incorporating an antigen in a non-CDR loop region
A modified immunoglobulin (Ig) molecule incorporates, preferably in one or more non-CDR loops, one or more foreign antigenic peptides such as a ras peptide. The antigen binding site of the...
|
|
|
6274347 |
Method of producing a cell surface bound lam-1 specific antibody
A shed form of leukocyte adhesion molecule-1 (LAM-1, L-selectin) is present in high levels in human plasma. Quantitative methods of detecting shed LAM-1 (sLAM-1) by Western blot and ELISA analysis...
|
|
|
6271352 |
PAI-1 determination and use thereof
a monoclonal antibody which binds a human endothelial type plasminogen activator inhibitor (PAI-1) produced by dexamethasone-treated human HT-1080 fibrosarcoma cells may be used, inter alia, for...
|
|
|
6262239 |
TNF receptor-specific antibodies
Antibodies to Tumor Necrosis Factor receptors (TNF-Rs) which inhibit the cytocidal effect of TNF but not its binding to the TNF-Rs, and ligands interacting with other receptors of the TNF/NGF...
|
|
|
6258359 |
Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
There is provided an immunogenic composition capable of inducing protective antibodies against Helicobacter infection characterized in that it comprises: i) at least one sub-unit of a urease...
|
|
|
6255459 |
Antibodies to a G protein-activated, inward rectifying KGA potassium channel
The invention provides antibodies directed against a G protein-activated, inward rectifying KGA potassium channel polypeptide.
|
|
|
6251395 |
Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies
Methods to inhibit inflammation and macrophage infiltration following spinal cord injury are disclosed along with methods to modulate TNFα release from cells expressing α d are disclosed.
|
|
|
6245897 |
Monoclonal antibody recognizing cell surface antigen CD14
A monoclonal antibody which recognizes lipopolysaccharide binding site of macrophage cell surface receptor CD14 and has binding activity to monocyte or macrophage cells. The monoclonal antibody...
|
|
|
6242575 |
Antibodies for detecting p27 protein
The subject invention provides an isolated protein having an apparent molecular weight of about 27 kD and capable of binding to and inhibiting the activation of a cyclin E-Cdk2 complex. The subject...
|
|
|
6242576 |
Monoclonal and polyclonal antibodies relating to fragile X syndrome
The DNA sequence spanning the fragile X site on the X human chromosome has been obtained in purified and isolated form. As fragile X is associated with mental retardation, the availability of a DNA...
|
|
|
6232446 |
TNF ligands
Antibodies to tumor necrosis factor receptors (TNF-Rs) are disclosed together with methods of producing them. The antibodies are preferably those which inhibit the cytotoxic effect of TNF but not...
|
|
|
6231857 |
Antibodies to S. mutans and uses thereof
The invention describes three monoclonal IgG antibodies, referred to as SWLA1, SWLA2, and SWLA3, which appear to recognize a species-specific lipooligosaccharide or lipopolysaccharide on the cell...
|
|
|
6228360 |
Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.
|
|
|
6221353 |
Antibodies Which Bind Mycobacterial Tuberculosis Proteins
Antibodies that bind Mycobacterium tuberculosis 28 kDa proteins and immune complexes between the antibodies and proteins.
|
|
|
6217866 |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
Hybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells...
|
|
|
6214342 |
Method for increasing mean survival times of transplants with LFA-1-specific antibodies
Mean survival times of a functional transplant of solid organs in a patient are increased by administering to the patient an initial dosing of a therapeutically effective amounts of a monoclonal...
|
|
|
6214974 |
Avidin-biotin immunoconjugates
The present invention provides a non-viral vector, comprising a cell binding component having a biotin-binding element conjugated to a biotinylated moiety. Also, provided is a method of introducing...
|